Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study

Luigi Celio, Gabriella Saibene, Stefano Lepori, Fabrizio Festinese, Monica Niger, Francesco Raspagliesi, Domenica Lorusso

Research output: Contribution to journalArticle

Abstract

Purpose: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. Methods: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27). The primary endpoint was total control (TC; no vomiting, no rescue antiemetics, and no nausea) on days 2–5, using a diary. Secondary endpoints included proportion of patients with no emesis impact on daily life using the Functional Living Index–Emesis (FLIE) questionnaire, and patient’s satisfaction with antiemetic coverage. Results: Fifty-two percent of patients in arm A (P=0.406), 59% in arm B (P=0.779), and 67% in arm C had a delayed TC. Secondary analyses showed no significant difference across arms in any efficacy endpoint. FLIE scores as well as mean satisfaction scores were similar across arms. Conclusions: In this exploratory study with a small sample size, we did not find any clue about better control of delayed emesis with either olanzapine regimen in gynecologic cancer patients treated with carboplatin/paclitaxel and receiving the same prophylaxis for acute emesis.

Original languageEnglish
Pages (from-to)253-258
Number of pages6
JournalTumori
Volume105
Issue number3
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

olanzapine
Carboplatin
Paclitaxel
Vomiting
Dexamethasone
Neoplasms
Antiemetics
Patient Satisfaction
Sample Size
Nausea
Prospective Studies
Drug Therapy

Keywords

  • Carboplatin
  • CINV
  • emesis
  • olanzapine
  • palonosetron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer : a randomised study. / Celio, Luigi; Saibene, Gabriella; Lepori, Stefano; Festinese, Fabrizio; Niger, Monica; Raspagliesi, Francesco; Lorusso, Domenica.

In: Tumori, Vol. 105, No. 3, 01.06.2019, p. 253-258.

Research output: Contribution to journalArticle

@article{ba4d63bb16d445119eeb8074007c277a,
title = "Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study",
abstract = "Purpose: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. Methods: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27). The primary endpoint was total control (TC; no vomiting, no rescue antiemetics, and no nausea) on days 2–5, using a diary. Secondary endpoints included proportion of patients with no emesis impact on daily life using the Functional Living Index–Emesis (FLIE) questionnaire, and patient’s satisfaction with antiemetic coverage. Results: Fifty-two percent of patients in arm A (P=0.406), 59{\%} in arm B (P=0.779), and 67{\%} in arm C had a delayed TC. Secondary analyses showed no significant difference across arms in any efficacy endpoint. FLIE scores as well as mean satisfaction scores were similar across arms. Conclusions: In this exploratory study with a small sample size, we did not find any clue about better control of delayed emesis with either olanzapine regimen in gynecologic cancer patients treated with carboplatin/paclitaxel and receiving the same prophylaxis for acute emesis.",
keywords = "Carboplatin, CINV, emesis, olanzapine, palonosetron",
author = "Luigi Celio and Gabriella Saibene and Stefano Lepori and Fabrizio Festinese and Monica Niger and Francesco Raspagliesi and Domenica Lorusso",
year = "2019",
month = "6",
day = "1",
doi = "10.1177/0300891619839301",
language = "English",
volume = "105",
pages = "253--258",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer

T2 - a randomised study

AU - Celio, Luigi

AU - Saibene, Gabriella

AU - Lepori, Stefano

AU - Festinese, Fabrizio

AU - Niger, Monica

AU - Raspagliesi, Francesco

AU - Lorusso, Domenica

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. Methods: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27). The primary endpoint was total control (TC; no vomiting, no rescue antiemetics, and no nausea) on days 2–5, using a diary. Secondary endpoints included proportion of patients with no emesis impact on daily life using the Functional Living Index–Emesis (FLIE) questionnaire, and patient’s satisfaction with antiemetic coverage. Results: Fifty-two percent of patients in arm A (P=0.406), 59% in arm B (P=0.779), and 67% in arm C had a delayed TC. Secondary analyses showed no significant difference across arms in any efficacy endpoint. FLIE scores as well as mean satisfaction scores were similar across arms. Conclusions: In this exploratory study with a small sample size, we did not find any clue about better control of delayed emesis with either olanzapine regimen in gynecologic cancer patients treated with carboplatin/paclitaxel and receiving the same prophylaxis for acute emesis.

AB - Purpose: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. Methods: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27). The primary endpoint was total control (TC; no vomiting, no rescue antiemetics, and no nausea) on days 2–5, using a diary. Secondary endpoints included proportion of patients with no emesis impact on daily life using the Functional Living Index–Emesis (FLIE) questionnaire, and patient’s satisfaction with antiemetic coverage. Results: Fifty-two percent of patients in arm A (P=0.406), 59% in arm B (P=0.779), and 67% in arm C had a delayed TC. Secondary analyses showed no significant difference across arms in any efficacy endpoint. FLIE scores as well as mean satisfaction scores were similar across arms. Conclusions: In this exploratory study with a small sample size, we did not find any clue about better control of delayed emesis with either olanzapine regimen in gynecologic cancer patients treated with carboplatin/paclitaxel and receiving the same prophylaxis for acute emesis.

KW - Carboplatin

KW - CINV

KW - emesis

KW - olanzapine

KW - palonosetron

UR - http://www.scopus.com/inward/record.url?scp=85067904448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067904448&partnerID=8YFLogxK

U2 - 10.1177/0300891619839301

DO - 10.1177/0300891619839301

M3 - Article

C2 - 30945623

AN - SCOPUS:85067904448

VL - 105

SP - 253

EP - 258

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -